CX Venture Group
1
16M
0
0.03
- Stages of investment
- Areas of investment
Summary
CX Venture Group is the famous VC, which was founded in 1990. The leading representative office of defined VC is situated in the Taipei. The company was established in Asia in Taiwan.
The important activity for fund was in 2005. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Among the most successful fund investment fields, there are Therapeutics, Biotechnology. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Cellerant Therapeutics
The typical case for the fund is to invest in rounds with 5 participants. Despite the CX Venture Group, startups are often financed by MPM Capital, Allen & Company. The meaningful sponsors for the fund in investment in the same round are Novel Bioventures, MPM Capital, George Rathmann. In the next rounds fund is usually obtained by MPM Capital, Camelot Venture Group.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.03
- Investments by region
-
- United States (1)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cellerant Therapeutics | 11 May 2005 | Biotechnology, Therapeutics, Clinical Trials | Early Stage Venture | 16M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.